Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IA Dexamethasone and Ketorolac for Refractory Headache
NCT04353505Phase 1Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketorolac and dexamethasone in chronic migraine, Cluster Headache (CH) and trigeminal neuralgia (TN), sponsored by Weill Cornell Medicine. Planned start Oct 2020; status: withdrawn.
02
Drugs
ketorolacdexamethasone
03
Conditions
chronic migraineCluster Headache (CH)trigeminal neuralgia (TN)
Beyond the preview
Go deeper on NCT04353505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04353505.